β-1 and β-2 adrenoceptor polymorphisms:: Functional importance, impact on cardiovascular diseases and drug responses

被引:100
作者
Brodde, Otto-Erich [1 ]
机构
[1] Univ Essen Gesamthsch, Sch Med, Dept Pathophysiol, D-45147 Essen, Germany
关键词
D O I
10.1016/j.pharmthera.2007.07.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
beta-1 and beta-2 adrenoceptors (AR) play a pivotal role in regulation of the activity of the sympathetic nervous system and agonists and antagonists at both beta AR subtypes are frequently used in treatment of cardiovascular diseases. Both beta-1 and beta-2 AR genes have several polymorphisms that encode different amino acids. This review summarizes new insights into the functional importance of these polymorphisms, as well as their relationship to cardiovascular diseases and their impact on responses to adrenergic drug treatment. At present, it seems that, for cardiovascular diseases, beta-1 and beta-2 AR polymorphisms do not play a role as disease-causing genes; they might, however, be associated with disease-related phenotypes. In addition they could influence adrenergic drug responses. Thus, the Arg(389)Gly beta-1 AR polymorphism might predict responsiveness to beta-1 AR agonist and blocker treatment: patients homozygous for the Arg(389) beta-1 AR polymorphism should be good responders, while patients homozygous for the Gly(389) beta-1 AR polymorphism should be poor or nonresponders. Furthermore, the Arg(16)Gln(27) beta-2 AR seems to have strong impact on long-term agonist-induced beta-2 AR desensitization. Thus, patients carrying this haplotype appear to suffer from rapid loss of therapeutic efficacy of chronic agonist treatment, as has been demonstrated in asthma patients. Moreover, the Arg(16)Glu(27) beta-2 AR haplotype might have some predictive value for poor outcome of heart failure. Future large prospective studies have to replicate these findings in order to reach the final goal of pharmacogenomic research: to optimize and individualize drug therapy based on the patient's genetic determinants of drug efficacy. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 29
页数:29
相关论文
共 193 条
[71]   Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial [J].
Israel, E ;
Chinchilli, VM ;
Ford, JG ;
Boushey, HA ;
Cherniack, R ;
Craig, TJ ;
Deykin, A ;
Fagan, JK ;
Fahy, JV ;
Fish, J ;
Kraft, M ;
Kunselman, SJ ;
Lazarus, SC ;
Lemanske, RF ;
Liggett, SB ;
Martin, RJ ;
Mitra, N ;
Peters, SP ;
Silverman, E ;
Sorkness, C ;
Szefler, SJ ;
Wechsler, ME ;
Weiss, ST ;
Drazen, JM .
LANCET, 2004, 364 (9444) :1505-1512
[72]   The effect of polymorphisms of the β2-adrenergic receptor on the response to regular use of albuterol in asthma [J].
Israel, E ;
Drazen, JM ;
Liggett, SB ;
Boushey, HA ;
Cherniack, RM ;
Chinchilli, VM ;
Cooper, DM ;
Fahy, JV ;
Fish, JE ;
Ford, JG ;
Kraft, M ;
Kunselman, S ;
Lazarus, SC ;
Lemanske, RF ;
Martin, RJ ;
McLean, DE ;
Peters, SP ;
Silverman, EK ;
Sorkness, CA ;
Szefler, SJ ;
Weiss, ST ;
Yandava, CN .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (01) :75-80
[73]   Arg389Gly polymorphism of the human β1-adrenergic receptor in patients with nonfatal acute myocardial infarction [J].
Iwai, C ;
Akita, H ;
Kanazawa, K ;
Shiga, N ;
Terashima, M ;
Matsuda, Y ;
Takai, E ;
Miyamoto, Y ;
Shimizu, M ;
Kajiya, T ;
Hayashi, T ;
Yokoyama, M .
AMERICAN HEART JOURNAL, 2003, 146 (01) :106-109
[74]   Suppressive effect of the Gly389 allele of the β1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy [J].
Iwai, C ;
Akita, H ;
Shiga, N ;
Takai, E ;
Miyamoto, Y ;
Shimizu, M ;
Kawai, H ;
Takarada, A ;
Kajiya, T ;
Yokoyama, M .
CIRCULATION JOURNAL, 2002, 66 (08) :723-728
[75]   β2-Adrenoceptor gene polymorphisms and blood pressure variations in East Anglian Caucasians [J].
Jia, HY ;
Sharma, P ;
Hopper, R ;
Dickerson, C ;
Lloyd, DD ;
Brown, MJ .
JOURNAL OF HYPERTENSION, 2000, 18 (06) :687-693
[76]   Association analysis of Arg16Gly polymorphism of the β2-adrenergic receptor gene in offspring from hypertensive and normotensive families [J].
Jindra, A ;
Horky, K ;
Peleska, J ;
Jáchymová, M ;
Bultas, J ;
Umnerová, V ;
Heller, S ;
Hlubocká, Z .
BLOOD PRESSURE, 2002, 11 (04) :213-217
[77]  
Johnson JA, 2005, CURR OPIN MOL THER, V7, P218
[78]   β1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol [J].
Johnson, JA ;
Zineh, I ;
Puckett, BJ ;
McGorray, SP ;
Yarandi, HN ;
Pauly, DF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (01) :44-52
[79]   β-adrenergic receptor polymorphisms:: Cardiovascular disease associations and pharmacogenetics [J].
Johnson, JA ;
Terra, SG .
PHARMACEUTICAL RESEARCH, 2002, 19 (12) :1779-1787
[80]   Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of β-blockers at Gly389-β1-adrenoceptors compared to Arg389-β1-adrenoceptors [J].
Joseph, SS ;
Lynham, JA ;
Grace, AA ;
Colledge, WH ;
Kaumann, AJ .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 142 (01) :51-56